ANNOUNCEMENTS
Awards, accelerator programmes, clinical engagement and international events as DiabSense advances its diabetic-foot imaging platform.
LATEST UPDATES
Follow key moments in the development of DiabSense and the FootScan platform.
DiabSense will present its connected diabetic-foot monitoring platform at AsiaBerlin Summit 2026 in Berlin from 23–27 November 2026, joining cross-border innovators, partners and healthcare stakeholders from Asia and Europe.
View announcement ↗
DiabSense has graduated from the HEMAS Slingshot accelerator programme, marking the completion of an important phase of commercial mentoring, venture development and healthcare-industry engagement. The programme supported the team as it advances the FootScan portfolio and connected diabetic-foot monitoring platform.
View announcement ↗
DiabSense, developed in collaboration with ExcelTech, has been recognised as the National Winner in the Best Innovative Product in HealthTech category at the SLASSCOM National Ingenuity Awards 2026. Presented at the awards ceremony held on 16 June 2026 in Colombo, the recognition highlights the team's commitment to developing impactful technologies for improved diabetes care and patient outcomes.
View announcement ↗
DiabSense has successfully graduated from Batch 7 of the Health Founders Accelerator Programme in Estonia. The programme supported the team in refining its clinical validation pathway, regulatory strategy, product roadmap, global market positioning and investor readiness. Following this milestone, DiabSense will continue advancing its FootScan platform, expanding clinical collaborations and preparing for international partnerships.
View announcement ↗
DiabSense participated in the AsiaBerlin Summit 2025 at the Sri Lanka Pavilion in Berlin, presenting its visual and thermal-imaging platform for the early detection of diabetic foot risks. The event created new opportunities to discuss clinical pilots, strategic partnerships and international market expansion with stakeholders from across Asia and Europe.
View announcement ↗
DiabSense has been selected to join the Slingshot 3.0 cohort organised by Hemas Holdings and Hatch Works. The programme provides a valuable platform to strengthen the venture's commercial strategy, engage with industry mentors and accelerate the development of innovative solutions for diabetes care.
View announcement ↗
DiabSense presented its diabetic foot risk-detection solution to vascular surgeons at VSICON 2025 in India. The conference offered an important opportunity to introduce the platform to specialist clinicians, gather expert perspectives and explore how visual and thermal imaging could support earlier identification and prevention of diabetic foot complications.
View announcement ↗
DiabSense participated in VSICON 2025, engaging with vascular surgeons, professors and clinical innovators working at the forefront of vascular care. The event enabled the team to exchange insights on diabetic foot ulcer prevention and discuss the potential role of accessible imaging technologies in supporting diagnosis, monitoring and timely clinical intervention.
View announcement ↗
DiabSense has been named the winner of Venture Engine 2025. The award recognises the team's vision, resilience and commitment to developing healthcare technologies with the potential to improve diabetes care internationally. The achievement was made possible through the support of the Lankan Angel Network, Venture Engine mentors, partners, advisers and the wider DiabSense and ExcelTech teams.
View announcement ↗
DiabSense has been selected for Batch 7 of the Health Founders Pre-Accelerator programme. Through focused sessions on market opportunity, team development, business traction and fundraising, the programme will help the team refine its strategy and strengthen its mission to support earlier detection and prevention of diabetic foot complications.
View announcement ↗Interested in clinical collaboration, strategic partnerships or the FootScan platform?
